B

Boston Scientific

Medical devices maker for interventional specialties

Product Specialist - Peripheral Interventions, Sales

Full-TimeUpdated
No salary listed
Senior
Bachelor's
Singapore
In Person
Sales & Account ManagementField Sales

About the job

Requirements
  • A degree in Biomedical, Science, Nursing, or a related field is required.
  • A minimum of 5 years of sales experience in the healthcare sector is required.
  • The ability to engage with clinicians and a variety of stakeholders is required.
  • Experience attending cases and providing support in the operating room is required.
Responsibilities
  • Develop as a professional sales representative by acquiring working knowledge and selling techniques, and address a variety of issues using general knowledge of the medical device industry, Boston Scientific, and competitors.
  • Visit existing and potential Boston Scientific customers regularly and according to plan to promote products and services and achieve agreed monthly, quarterly, and yearly sales targets.
  • Manage existing customers and acquire new customers in the assigned territory under the Manager's general supervision.
  • With limited instruction from the Manager, plan and develop the market for existing and new products according to divisional goals and objectives, executing plans while optimizing available tools such as consignment.
  • Provide ongoing technical training and support directly to customers in catheterization laboratories.
  • Cultivate business relationships with hospital management, purchasing departments, and hospital staff.
  • Attend meetings, conferences, and exhibitions as required to promote Boston Scientific products and services.
  • Analyze and report market and business feedback to the Manager and/or others monthly and yearly using available support tools.

About the company

B

Boston Scientific

View
Website

Boston Scientific designs and makes medical devices used in procedures across cardiology, endoscopy, urology, and neuromodulation. Its products help doctors diagnose and treat conditions by guiding minimally invasive interventions and delivering therapies inside the body, with revenue from hospitals and clinics. The firm differentiates itself through a broad, global portfolio and heavy ongoing investment in research and development to expand capabilities and address complex health issues. Its goal is to improve patient care by providing reliable, effective medical devices and solutions that enable clinicians to perform safer, more effective procedures while growing its business.

Company Size

10,001+

Company Stage

IPO

Headquarters

Marlborough, Massachusetts

Founded

1979

Get referred to Boston Scientific

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 11, 2026 FDA clearance for SpaceOAR Flex expands prostate cancer workflow offerings.
  • Boston Scientific restored remote cardiac monitoring and most operations by September 8, 2026.
  • Second-quarter 2026 sales grew 7.5%, showing strong demand before the cyber disruption.

What critics are saying

  • August 25, 2026 cyberattack forced Boston Scientific to miss 2026 sales and profit guidance.
  • September 25, 2026 FDA Class I recall removed Imager II Angiographic Catheters after tip defects.
  • AXIOS and Infinion CX recalls show repeated manufacturing and design-quality failures across franchises.

What makes Boston Scientific unique

  • FARAPULSE remains Boston Scientific's category-defining pulsed-field ablation franchise in 2026.
  • SpaceOAR Flex extends a differentiated prostate-radiotherapy portfolio with real-time flexible delivery.
  • Global scale across cardiology, endoscopy, urology, and neuromodulation diversifies procedure-dependent revenue.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Relocation Assistance
  • Performance Bonus

Growth & Insights and Company News

6 month growth

0%

1 year growth

12%

2 year growth

12%
Paki Kista
Oct 29th, 2026
Boston Scientific slashes 2026 guidance third time.

Boston Scientific slashes 2026 guidance third time. By Trisna Anggraini October 29, 2026 Boston Scientific reported a challenging third quarter, marked by a cyberattack and ongoing struggles in key product lines, prompting the company to slash its 2026 earnings and sales guidance for the third consecutive time. The medical device company now projects full-year revenue growth of 4.25%, down from a previous range of 5.5% to 6.5%. Adjusted earnings per share guidance was cut to $3.16 to $3.18 from $3.28 to $3.32, following an earlier February forecast of $3.43 to $3.49. The new guidance, released along with third-quarter results, is a far cry from what was projected at the beginning of the year, when Boston Scientific outlined 2026 sales growth expectations of 10.5% to 11.5%. The third-quarter results included a roughly $150 million revenue hit from a cyberattack that disrupted ordering, manufacturing, and shipping operations. This markedly lower impact compared with the $755 million in revenue losses attributed to a similar cyberattack during the year-ago period, showing the company's ongoing vulnerability to operational disruptions. Overall, Boston Scientific reported $5.14 billion in revenue, representing 1.5% growth compared to the prior year. CEO Mike Mahoney attributed the guidance reductions to persistent challenges in the Watchman and electrophysiology divisions, which historically drove significant growth. Watchman sales fell 6% year-over-year, while electrophysiology declined 5%, contrasting with 30% growth in Watchman sales and triple-digit gains in electrophysiology during 2025. Mahoney highlighted that the slowdown in the left atrial appendage closure market, which includes Watchman, stems from changes in patient identification and referral patterns, while electrophysiology's decline reflects competitive pressures in pulsed field ablation technology. The company also forecast a 3% to 1% sales decline in the fourth quarter and acknowledged that it will be challenged to grow sales and adjusted EPS next year. Boston Scientific's stock dropped nearly 7% to $42.02 following the announcement. The company also delayed its $14.5 billion acquisition of Penumbra, now expecting completion in early 2027 rather than 2026 due to the regulatory process taking a bit of time. "The regulatory process has taken a bit of time," Mahoney said. "We're still very confident in closing the transaction, but based on some of the discussions with the regulatory authorities, we anticipate the early first quarter close."

Asianet News
Oct 28th, 2026
BSX stock crashes to 4-year lows: Boston Scientific sees Q4 sales declining, CEO remains confident in 'long-term strategy'

BSX stock crashes to 4-year lows: Boston Scientific sees Q4 sales declining, CEO remains confident in 'long-term strategy' Published: Oct 28 2026, 09:10 PM IST * FB * TW * Linkdin * Whatsapp * GNFollow Us For full year 2026, Boston Scientific expects reported sales growth of about 4.25%, down from its previous forecast of 5.5% to 6.5%. * The company lowered its full-year adjusted earnings outlook to $3.16 to $3.18 per share, down from $3.28 to $3.32 per share. * Q3 net sales rose 1.5% to $5.14 billion, exceeding Wall Street estimates of $5.04 billion, according to Fiscal.ai * Q4 net sales is expected to decline between 1% and 3% from a year earlier. Shares of Boston Scientific (BSX) tumbled 8% on Wednesday and hit their lowest level since October 2022 earlier in the session after the medical device maker lowered its annual sales outlook and said it expects fourth-quarter revenue to decline. BSX shares are on track for their fifth loss in six sessions. Boston Scientific cuts Q4 sales forecast. Boston Scientific said it expects fourth quarter (Q4) net sales to decline between 1% and 3% from a year earlier. For full year 2026, the company expects reported sales growth of about 4.25%, down from its previous forecast of 5.5% to 6.5%. Organic sales growth is projected at 3.75%, down from an earlier estimate of 5% to 6%. The company also lowered its full-year adjusted earnings outlook to $3.16 to $3.18 per share, down from $3.28 to $3.32 per share. Cybersecurity attack to disrupt FY 2026 financial performance. In August, Boston Scientific disclosed a cybersecurity incident that disrupted manufacturing, order processing, and shipments globally. The company subsequently warned that the disruptions would materially affect its 2026 financial performance, although it expected to recover some lost revenue as operations gradually resumed. On Wednesday, CEO Mike Mahoney acknowledged the difficult year but said he remained "confident in our long-term strategy," citing the company's product portfolio and pipeline of new technologies. Meanwhile, Q3 net sales rose 1.5% to $5.14 billion, exceeding Wall Street estimates of $5.04 billion, according to Fiscal.ai. Adjusted earnings per share slipped to $0.73 from $0.75 last year, but narrowly beat consensus estimates of $0.72 per share. Retail turns bullish on BSX. Despite the slump, retail sentiment surrounding BSX on Stocktwits flipped to 'bullish' from 'bearish' over the past 24 hours, amid 'high' message volumes. The stock has been under strong selling pressure so far this year, crashing more than 56%. Also read: WEN Stock Surges 15% As Trian Fund Offers $1.4B To Take The Burger Chain Private For updates and corrections, email newsroom[at]stocktwits[dot]com.< Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business. 0 Comments / 0 New

The Motley Fool
Oct 28th, 2026
Stock market today, Oct. 28: Boston Scientific slips 6% after cutting Q4 sales and full-year EPS guidance on cyberattack impact.

Stock market today, Oct. 28: Boston Scientific slips 6% after cutting Q4 sales and full-year EPS guidance on cyberattack impact. Today, Oct. 28, 2026, the medical device maker slashed profit expectations after an August cyberattack continued disrupting operations. BSX - Boston Scientific. $42.43 -$2.63 (-5.84%) NYSE · As of 4:00 PM ET 10/28/26 BSX · 1M -3.81% Key data points. Market cap $65.30B Day's range $39.57 - $43.92 52wk range $39.57 - $105.65 Volume 69.8M Avg volume 19.3M Gross margin 66.36% Boston Scientific (BSX -5.84%), a global medical device maker focused on interventional cardiology and specialty devices, closed at $42.44, down 5.81%. Investors are focused on the cyberattack's lingering disruption and the company's lower fourth-quarter and full-year guidance. Trading volume reached 66.8M shares, coming in about 234% above its three-month average of 20.0M shares. How the markets moved today. S&P 500 (^GSPC +0.28%) closed at 7,744, up 0.28%, while the Nasdaq Composite (^IXIC +0.27%) finished at 26,550, up 0.27%. In the medical devices sector, Medtronic (MDT +0.88%) closed at $94.82, up 0.93%, and Abbott Laboratories (ABT -0.45%) closed at $102.67, down 0.42%, after fresh outlook pressure kept the group in focus. What this means for investors. Boston Scientific guided for 3% to 5% sales growth and $0.80 to $0.82 in adjusted EPS for Q3, and came up shy of both figures today, delivering a 1.5% sales increase and $0.73 in adjusted EPS. Management blamed an eight-day disruption from a cyberattack as the primary culprit, estimating it cost the company 300 basis points in sales growth and $0.07 in adjusted EPS. Making matters worse, the company doesn't believe an immediate turnaround is in sight, guiding for 3.75% sales growth in 2026; rather, a slow rebuilding is more likely over the next year or two. CEO Mahoney explained, "We believe that 2027 will be the trough in the cycle and we have several investments and new innovations coming over the course of the next 3 years." That said, BSX shares now trade at just 13 times forward earnings, so it wouldn't take massive growth to potentially spark such a turnaround - especially considering the company may have upside incoming from its pending acquisition of Penumbra, if it can integrate the deal successfully. I'm keeping an eye on Boston Scientific from a distance, but I'd only want to invest once I start to see signs of progress. Is Boston Scientific a smart long-term play? Before you buy stock in Boston Scientific, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now... and Boston Scientific wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of its recommendation, you'd have $337,166!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of its recommendation, you'd have $1,339,143!* Now, it's worth noting Stock Advisor's total average return is 904% - a market-crushing outperformance compared to 213% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors. *Stock Advisor returns as of October 28, 2026.

Yahoo Finance
Oct 28th, 2026
Boston Scientific hit by cyber outage and cyclical slump, plans $500M savings as 2027 seen as trough

Boston Scientific said a cyber security incident hurt its third-quarter results, causing a two-week outage with eight business days of manufacturing and shipping disruption. The attack cut sales growth by about 300 basis points and earnings per share by $0.07, and lost revenue came to $150 million. The company expects 2027 to be the low point of its cycle, with recovery in 2028. Weakness in its electrophysiology and WATCHMAN franchises, and pricing pressure in China, weigh on growth. A restructuring programme should save more than $500 million over three years. It also booked an $80 million charge, mostly for product liability cases. The Penumbra acquisition is now expected to close in early 2027 because of regulatory timelines.

Transcript Daily
Oct 28th, 2026
Boston Scientific (NYSE:BSX) issues quarterly earnings results.

Boston Scientific (NYSE:BSX) issues quarterly earnings results. Boston Scientific (NYSE:BSX - Get Free Report) posted its quarterly earnings data on Wednesday. The medical equipment provider reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.01, FiscalAI reports. The business had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $5.06 billion. Boston Scientific's quarterly revenue was up 1.4% on a year-over-year basis. During the same period in the prior year, the business posted $0.75 EPS. Here are the key takeaways from Boston Scientific's conference call: * Q3 missed expectations: Organic revenue grew 1.5%, below the 3%-5% outlook, while adjusted EPS fell 3% to $0.73. The cybersecurity incident reduced revenue growth by roughly 300 basis points and EPS by approximately $0.07. * Boston Scientific expects continued near-term pressure, guiding to a 1%-3% organic revenue decline and adjusted EPS of $0.77-$0.79 in Q4. Management said 2027 revenue and EPS growth will be challenging as EP and WATCHMAN face market-share and competitive pressures, while China pricing headwinds intensify. * WATCHMAN sales declined 6% and EP sales declined 5% in Q3, with further EP share erosion expected until new products launch. The company also cited weaker urology performance, China-related pricing pressure, supply constraints, and delays affecting parts of its product pipeline. * Management expects a return to stronger performance in 2028, supported by launches including FARAWAVE Ultra, 2D ICE, CRM's Denali platform, new IVL and imaging technologies, and a potential Penumbra contribution. The company identified approximately $25 billion of new market opportunities by 2030. * A company-wide restructuring program is expected to generate more than $500 million in savings over three years, with over half anticipated by the end of 2027. Boston Scientific said the program should improve operating leverage while preserving investment in key growth platforms. Boston Scientific stock down 7.9%. Boston Scientific stock traded down $3.55 during midday trading on Wednesday, reaching $41.51. The company's stock had a trading volume of 22,892,086 shares, compared to its average volume of 18,425,303. Boston Scientific has a fifty-two week low of $39.57 and a fifty-two week high of $105.65. The business has a 50-day simple moving average of $45.29 and a 200-day simple moving average of $57.71. Analyst ratings changes. BSX has been the subject of a number of analyst reports. Stifel Nicolaus reduced their price objective on shares of Boston Scientific from $60.00 to $55.00 and set a "buy" rating for the company in a research note on Monday. Raymond James Financial reissued an "outperform" rating and issued a $57.00 price objective (down from $78.00) on shares of Boston Scientific in a research note on Thursday, July 30th. Evercore cut their price objective on Boston Scientific from $65.00 to $52.00 and set an "outperform" rating on the stock in a research report on Wednesday, October 7th. Piper Sandler reduced their price target on Boston Scientific from $65.00 to $60.00 in a research report on Wednesday, July 29th. Finally, Canaccord Genuity Group lowered their target price on shares of Boston Scientific from $70.00 to $66.00 and set a "buy" rating for the company in a research note on Thursday, July 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $65.93. Key headlines impacting Boston Scientific. Here are the key news stories impacting Boston Scientific this week: * Boston Scientific reported third-quarter revenue of $5.138 billion, up 1.5% year over year and ahead of analysts' expectations of approximately $5.06 billion. Adjusted EPS of $0.73 also narrowly exceeded the $0.72 consensus estimate. * The company highlighted operational progress, including enrollment in the Elite AF clinical trial and FDA 510(k) clearances for StoneSmart technologies and an expanded SEISMIQ catheter offering. Cardiovascular sales rose 1.9% on a reported basis, while Latin American sales increased 16%. * Management's results extended Boston Scientific's streak of quarterly earnings beats, but the underlying growth rate remains modest. Revenue increased from $5.065 billion a year earlier, while regional performance was uneven, including a 0.6% decline in Asia-Pacific sales. * Boston Scientific again lowered its fiscal 2026 outlook, now targeting approximately 4.25% reported net-sales growth. Management expects fourth-quarter reported and organic sales to decline 1% to 3%, signaling a difficult finish to the year. * The cybersecurity incident has disrupted business operations and weighed on the company's forecast. Investors appear to be treating the reduced guidance as more important than the quarterly beat, raising concerns about near-term execution and the duration of the incident's financial impact. * Profitability also weakened year over year: GAAP EPS fell to $0.40 from $0.51, while adjusted EPS declined from $0.75 to $0.73. The combination of lower earnings, cybersecurity-related uncertainty and another outlook reduction explains the negative investor reaction. Insider buying and selling. In related news, Director David C. Habiger acquired 2,100 shares of Boston Scientific stock in a transaction on Wednesday, August 5th. The stock was purchased at an average cost of $47.59 per share, with a total value of $99,939.00. Following the purchase, the director directly owned 17,160 shares in the company, valued at approximately $816,644.40. The trade was a 13.94% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Edward J. Ludwig purchased 5,000 shares of the business's stock in a transaction dated Friday, July 31st. The shares were bought at an average price of $45.48 per share, with a total value of $227,400.00. Following the purchase, the director directly owned 30,359 shares of the company's stock, valued at approximately $1,380,727.32. The trade was a 19.72% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have purchased 194,522 shares of company stock worth $9,385,210 in the last ninety days. 0.34% of the stock is owned by corporate insiders. Boston Scientific company profile. Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide. Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation. Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.